A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort

Annals of Indian Academy of Neurology

Volumn 17, Issue 1, 2014, Pages 77-79

  Barhate, Kavita Sohan ^a   Ganeshan, Malti ^a   Singhal, Bhim Sen ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

Myelitis; Neuromyelitis optica; Neuromyelitis optica spectrum disorders; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA1 INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN DAMAGE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INDIAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; SPINAL CORD LESION;

EID: 84898746791     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.128559     Document Type: Article

References (25)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
3. Jacob A, Boggild M. Neuromyelitis optica. Ann Indian Acad Neurol 2007;10:231-9.
4. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-71.
5. Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology 2010;74:736-42.
6. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-49.
7. Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: Comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011;82:1360-4.
8. Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84:922-30.
9. Lana-Peixoto MA, Callegaro D. The expanded spectrum of neuromyelitis optica: Evidences for a new definition. Arq Neuropsiquiatr 2012;70:807-13.
10. Sato D, Fujihara K. Atypical presentations of neuromyelitis optica. Arq Neuropsiquiatr 2011;69:824-8.
11. Sinnecker T, Dörr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012;79:708-14.
12. Sato DK, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80:2210-6.
13. Yanagawa K, Kawachi I, Toyoshima Y, Yokoseki A, Arakawa M, Hasegawa A, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009;73:1628-37.
14. Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013;80:2194-200.
15. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-204.
16. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-32.
17. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.
18. Jarernsook B, Siritho S, Prayoonwiwat N. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. Mult Scler 2013;19:585-92.
19. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Mult Scler 2012;18:1480-3.
20. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-8.
21. Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013;260:627-34.
22. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol 2013;12:554-62.
23. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013;70:394-7.
24. Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314-22.
25. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica antiaquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013;73:77-85.